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Synthesis of new allyl palladium complexes
bearing purine-based NHC ligands with
antiproliferative and proapoptotic activities
on human ovarian cancer cell lines†
Thomas Scattolin,a Isabella Caligiuri,b Luciano Canovese, a Nicola Demitri,c
Roberto Gambari, d Ilaria Lampronti, d Flavio Rizzolio,a,b Claudio Santoa and
Fabiano Visentin *a
A series of new palladium allyl complexes bearing purine-based carbenes derived from caﬀeine, theo-
phylline and theobromine have been prepared and characterized by NMR spectroscopy, and elemental
analysis and in two cases by single crystal X-ray diﬀraction. The cytotoxic and proapoptotic activities of
compounds have been determined in vitro on human ovarian cancer A2780 and SKOV-3 cell lines. These
experiments have shown that the palladium-allyl fragment induces a general cytotoxicity, but the choice
of the supporting ligands is of paramount importance for achieving the best results. In particular com-
plexes 4c, 4d and 5d exhibit a higher antiproliferative eﬀect (IC50: 0.09, 0.81 and 0.85 μM respectively)
than cisplatin (IC50: 1.5 μM) on A2780 cells, and 4d (IC50: 1.7 μM vs. 5.94 μM) on SKOV-3 cell line.
Moreover in many cases it has been proved that the cytotoxicity of our complexes is associated with the
induction of apoptosis.
Introduction
In the last few decades, many eﬀorts have been made to
develop new strategies against neoplastic pathologies. Even in-
organic chemists have taken part in this challenge and starting
from the epoch-making discovery of the anti-cancer properties
of cisplatin,1 many researchers have invested their best eﬀorts
into planning and preparing new metal-based drugs, but
unfortunately not obtaining the exciting results of the early
years.2 The general problem of the pharmacologic approach to
cancer lies in the diﬃculty of predicting every possible inter-
action of the drug with the huge number of biomolecules
occurring in cellular and extra-cellular systems. The specificity
of a metal-based anticancer drug mainly depends on the possi-
bility that the metal centre directly binds to the biological
target, thus altering its functionality. DNA is the most recur-
ring genomic target and the ability of platinum to coordinate
strongly to nucleic acid, forming intrastrand crosslinks, is the
reason for the eﬀectiveness of cisplatin and its second and
third generation analogues.3,4 A lot of studies have sub-
sequently proved that many potential metal-based anticancer
drugs have non-genomic targets (usually proteins) regulating
the cell cycle or inhibiting the over-expressed enzymes present
in the cancer cells.2d,5
Unfortunately, a possible reactivity with biomolecules
diﬀerent from the specific diseased sites may induce a general
toxicity, which is often the accompanying side eﬀect of che-
motherapeutic drugs.
In principle, a better selectivity could be obtained when the
metal has a structural role i.e. it is helpful to achieve the
appropriate shape of the complex. In these cases binding to
the molecular target occurs through non-covalent interactions
in a manner similar to most organic drugs. Within this
context, the problem lies in the actual diﬃculty of precisely
defining the shape and size of the target site and consequently
synthesizing the appropriately tailored compounds.2g
These preliminary remarks highlight that the rational
design of a metal-based anticancer drug is an elegant but
often impracticable strategy. Therefore an extensive screening
of anti-tumour properties of diﬀerent metal compounds may
compensate for our inability to control their almost unpredict-
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able reactivity in the bloodstream and cellular environment. In
our decision to contribute to this systematic search we have
preliminarily set some guidelines suggested by previous contri-
butions to the literature. Firstly, we have opted for palladium-
based compounds. Palladium complexes have structures and
reactivity strictly comparable to platinum analogues and in
several cases have shown better anti-cancer activity than cispla-
tin.6 However, the fast dissociation pattern of palladium com-
plexes compared to platinum7 poses a problem since the spe-
ciation, which heavily aﬀects the biological activity and the
pharmacokinetic properties, might be increased. To remedy
this contraindication the most direct option is to introduce
ligands firmly anchored to the metal. For this reason we
planned to employ N-heterocyclic carbenes (NHCs), which are
known to form strong σ-bonds with most of the transition
metals.8 Moreover, several NHC–palladium complexes have
already exhibited an interesting cytotoxic activity9,6a,e and
tumour growth suppression even in vivo.6e
A potential improvement introduced in our work is the use
of some innovative NHC ligands with a purinic framework10 in
the hope that the natural imprint of the moiety could make
our palladium complexes more compatible with the biological
matrix (Chart 1). This kind of synergy has already given inter-
esting outcomes and in the most favourable cases the ligand
has become a real targeting vector of the metal compound.11
Furthermore, with the aim of enhancing the versatility of
our palladium complexes, sometimes also isocyanides or phos-
phines have been introduced into the coordination sphere.
Among the latter we tested PTA (1,3,5-triaza-7-phosphadaman-
tane) and TPPTS (3,3′,3″-phosphinetribenzenesulfonate),
which can increase the water-solubility of the metal com-
pounds and thereby make their pharmacologic application
easier.12
However, the most original contribution of this paper is
represented by the first attempt to utilize the palladium-η3-
allyl organometallic function for preparing compounds with
cytotoxic properties. This organometallic fragment is well
known for its involvement in numerous catalytic processes
(the most famous is the Tsuji–Trost reaction)13 but its behav-
iour in biological systems remains an almost unexplored field.
In previous studies, some of us have prepared numerous com-
pounds based on this functional group and studied their pro-
perties and reactivity.14 This experience suggests that the allyl
residue could: (a) remain bound to the metal centre, confer-
ring a specific shape to the complex and thereby allowing it to
be hosted in an active biological site; and (b) be released in
the cellular environment and thus directly interact with some
potential bio-target. The main goal of this paper is not to
resolve this intricate question but analyse its practical conse-
quences. Therefore, in order to verify the eﬀects of our new
palladium complexes, the potential antiproliferative activity
was tested on two tumour cell lines (A2780 and SKOV-3) dis-
playing a diﬀerent sensitivity to cisplatin and for four repre-
sentative complexes also on normal human fibroblasts MRC5.
To obtain further information on the possible mechanism(s)
of action, apoptosis was analysed as pro-apoptotic activity of
palladium compounds.15
Results and discussion
Synthesis of imidazolium salts from functionalized xanthines
Compounds 1b,16a 1c16b and 1d17 were re-synthesized adopting
a slightly modified literature procedure (Scheme 1). We have
chosen conditions that are not particularly severe and the reac-
tion of theophylline or theobromine with two equivalents of
benzyl-bromide (for 1b and 1d) or 1-(phenyl)propargyl-3-chlo-
ride (for 1c), carried out in DMF at R.T. overnight, gave the
functionalized bases in good yields (93–95%).
Despite the low reactivity of the sp2 N9 atom, commercial
caﬀeine (1a), the alkylated theophyllines 1b, 1c and theobro-
mine 1d react with a small excess of Meerwein’s salt in CH3CN
at R.T. in the presence of Na2CO3 under a non-controlled atmo-
sphere to give the corresponding N9 methylated imidazolium
salts in one hour’s time (Scheme 2). Acetonitrile is probably
more suitable for promoting the nucleophilic substitution
than chlorinated solvents thanks to its high dielectric con-
stant, whereas the presence of Na2CO3 in heterogeneous phase
is necessary since the strong HBF4 acid that is partially formed
Chart 1 Purine-based NHC ligands used in this work.
Scheme 1 Synthesis of functionalized xanthines.
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from the hygroscopic Me3OBF4 could protonate the N9 nitro-
gen of the xanthine so that the ensuing derivative would be no
longer available for methylation.
As an example we report in Fig. S1 (see the ESI†) the 1H
NMR spectra related to the methylation of caﬀeine (1a), which
shows that, in the absence of Na2CO3, methyl caﬀeine 2a coex-
ists with its protonated counterpart, whereas only pure 2a
derivative was detected in solution when the base was added
to the reaction mixture.
In this respect, we think that the low yield obtained by
other authors in Meerwein’s salt mediated methylation of the
modified xanthines is probably due to this side reaction,
which makes the workup of the process diﬃcult.15,18
Synthesis of silver NHC complexes
We recently reported that the reaction between the imidazo-
lium salts 2a, 2b, 2d and Ag2O carried out in acetonitrile pro-
duces a 1 : 1 mixture of the corresponding silver bis-NHC com-
plexes 3 and AgBF4.
19 This result was confirmed by a combi-
nation of spectroscopic and analytical data such as microana-
lysis, NMR, ESI-MS spectra and in one case (3b) even X-ray
diﬀraction analysis. In this paper we have applied this protocol
for the synthesis of the new complex 3c. The disappearance of
the imidazolic proton and the typical shift of the silver-
coordinated carbon at ca. 187 ppm in the 1H and 13C NMR
spectra, respectively, represent simple tests to confirm the pre-
dictable outcome of the reaction (Scheme 3).
Synthesis of mixed NHC/phosphine and NHC/isocyanide
palladium η3-allyl complexes
For the synthesis of the palladium complexes 4–7 we can take
advantage of the presence of co-precipitated AgBF4 as a stoi-
chiometric by-product in the preparation of silver complexes 3.
As a matter of fact, this condition allows the final complexes to
be obtained through a one-pot reaction, by mixing the afore-
said mixture with a stoichiometric amount of palladium allyl
dimer and phosphine (PPh3, PTA, TPPTS) or isocyanide (DIC =
2,6-dimethylphenyl isocyanide) (Scheme 4). The precipitation
of silver chloride is the driving force of the process and an
indication of its progress. It is important to highlight that no
formation of complexes bearing carbene/carbene and phos-
phine–phosphine (or isocyanide–isocyanide) ligands has been
observed and therefore a selective separation of the carbene/
phosphine (or isocyanide) complexes is always possible from
the reaction mixture.
Scheme 2 Synthesis of imidazolium salts from functionalized
xanthines.
Scheme 3 Synthesis of silver NHC purine-based complexes.
Scheme 4 Synthesis of mixed NHC/phosphine and NHC/isocyanide palladium allyl complexes.
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The characterization of the thirteen new complexes 4a–d,
5a,b,d and 6a,b,d (compounds 7a,b,d were reported in one of
our previous studies19) was performed by NMR, IR and
elemental analysis. In particular, an accurate examination of
NMR spectra allows some specific features of these derivatives
to be elucidated, which we can summarize on the following
points:
(a) In every NMR spectrum of the complexes containing a
coordinated phosphine (4a–d and 5a,b,d) the presence of two
complete sets of signals is manifest. This is a consequence of
the coexistence of a couple of atropoisomers due to the hin-
dered rotation of the asymmetric carbene ligands around the
Pd–C bond. The two isomers are always present in virtually
equal amounts.
For the less sterically crowded isocyanide-complexes 6a,b,d
this restriction is not operative and thus only one set of signals
is observable in solution at room temperature.
(b) The presence in the 1H NMR spectra of five distinct
signals (for each atropoisomer) ascribable to allyl protons can
be explained by the presence of two diﬀerent spectator ligands
and by the absence of a rearrangement (η3–η1–η3 or syn–syn/
anti–anti) sometimes observed even at room temperature.20
(c) The coordination of PPh3 and PTA (for complexes 4a–d
and 5a,b,d, respectively) is proved by the marked downfield
shift of the two peaks (one for each atropoisomer) observed in
the 31P{1H}NMR spectra (Δδ = 30–45 ppm with respect to the
free phosphines).
(d) The coordination of DIC in complexes 6a,b,d is con-
firmed by the weak signal of the coordinated isocyanide
carbon at ∼150 ppm in the 13C{1H}1H NMR spectra and the
significantly highfield shift of the ortho methyl protons with
respect to their original position in the 1H NMR spectra of the
free ligand. This conclusion is also supported by the IR
spectra, which show an intense band at 2170 cm−1, attribu-
table to the CN stretching of the coordinated isocyanide.
(e) The resonances of carbene carbons are always found in
a narrow range between 180 and 190 ppm, confirming the
coordination of the purine-based NHC ligand at the palladium
(II) centre. Moreover, in the spectra of compounds 4a–d and
5a,b,d, these signals resonate as doublets due to the J2 coup-
ling with the cis-phosphine.
The cationic nature of synthesized derivatives is indirectly
confirmed by the presence in all IR spectra of an intense
absorption at around 1050 cm−1, ascribable to the BF4
− anion.
Synthesis of bis(NHC) palladium η3-allyl complexes
This class of complexes were synthesized by reacting a stoi-
chiometric mixture of silver precursors 3 and AgBF4 with palla-
dium allyl dimer in the presence of KI (Scheme 5). The
addition of potassium iodide is necessary to remove all the
silver from the reaction mixture.
Transmetallation proceeds in good yield and the resulting
cationic complexes were all stable in solution and in air.
The most significant conclusion that can be immediately
inferred from the NMR spectra of species 8 is the presence of
only one set of signals. This observation indicates that there is
a free rotation of the two N-heterocyclic carbene ligands
around the Pd–C bond and thus the three hypothetical atropoi-
somers deriving from hindered rotation are not distinguish-
able at room temperature.
The symmetric structure of these complexes is demon-
strated by the presence of only three signals ascribable to the
allylic fragment in the 1H NMR spectra (two doublets with
diﬀerent coupling constants for the syn and anti terminal
protons and a multiplet for the central proton) and two in the
13C{1H}NMR spectra.
Finally, the 13CNHC–Pd(II) resonances at about 185 ppm rep-
resent compelling evidence of the coordination of carbene
ligands to the palladium centre.
X-Ray crystal structure determination of 4a and 8d
Crystalline forms of 4a and 8d contain one crystallographically
independent palladium complex (Fig. 1 and 2). The complexes
bear a positive charge that is balanced by a BF4
− counterion,
located close to the allyl ligand, which represents the area
where the metal is more exposed (the shortest F⋯Pd contacts
are 3.50(1) Å in 4a and 3.489(8) Å in 8d). Palladium adopts
square planar coordination spheres with bond lengths and
angles (Table 2SI†) in agreement with the literature structural
data of complexes with similar ligands. A query on CSD
(version 5.38) using the allyl-Pd–NHC fragment produces
29 hits with an average bite angle of 68.3(6)° and 2.04(1) Å
Pd⋯Ccarbenic bond lengths (2.32(1) Å for Pd⋯P bonds). The
allyl ligand has poor steric bulk constraints and can adopt
alternative conformations, specular with respect to the palla-
dium coordination plane, as can be seen in more than half of
similar structures already published. Models show that the
xanthines minimize steric repulsions in the solid state, adopt-
Scheme 5 Synthesis of bis(NHC) palladium allyl complexes.
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ing a roughly perpendicular orientation with respect to the pal-
ladium coordination plane (85.68° in 4a and 69.19°–75.98° in
8d, in agreement with the average 79(9)° extracted from CSD).
The molecular model of 4a is well superimposable with the
related triphenylphosphine-(η3-allyl)-(tetramethylimidazolin-
2-ylidene)-palladium tetrafluoroborate complex21 (CCDC
number: 714135); the comparison highlights a degree of phos-
phine ligand conformational freedom (Fig. S27†), which can
be related to diﬀerent crystal packing contacts. Crystal packing
of 4a and 8d shows hydrophobic contacts among neighbour
molecules, involving several CH⋯π and minor π⋯π inter-
actions. Furthermore, structure 4a has cavities (258 Å3, esti-
mated using the PLATON22 ‘CALC VOID’ routine) filled with
disordered solvent molecules (one CH2Cl2 molecule for each
cavity).
Antiproliferative activity on human A2780, SKOV-3 and MRC-5
cell lines
The antiproliferative activity was assayed on two human cancer
cell lines: A2780 and SKOV-3. Stock solutions (25–50 mM) of
each complex were prepared in DMSO (8), H2O (5 and 7), or
DMSO/H2O (1/1) (4 and 6); the working solutions (5 mM,
500 μM, 50 μM and 5μM) were obtained using H2O only.
Preliminarily the stability of complexes was checked in a 1 : 1
DMSO-d6/D2O solution (4, 6 and 8) or D2O (5 and 7). After
48 hours at room temperature no degradation and no ligand
replacement was observed (see NMR spectra in Fig. S28–S30†).
All of the complexes 4a–d, 5a,b,d, 6a,b,d, 7a,b,d, and 8a–d
and the synthetic precursor [Pd(μ-Cl)(η3-C3H5)]2 have been
tested on the cisplatin-sensitive A2780 cell line and on the cis-
platin-resistant SKOV-3 cell line in comparison with cisplatin
(positive control) in order to evaluate the relative IC50 values
expressed in μM concentration. All the data obtained are
reported in Table 1 for both the analysed cell lines. As
expected, cisplatin was more active on A2780 cells (IC50 = 1.5 ±
0.2 μM) with respect to SKOV-3 cells (IC50 = 5.94 ± 0.08 μM). In
addition the results reported in Table 1 show that all the com-
plexes, except 7a, displayed good anti-proliferative eﬀects on
the cisplatin-sensitive A2780 cells. The most active of them are
derivatives 4c, 4d and 5d, which exhibit a greater activity than
the positive control cisplatin (IC50: 1.5 ± 0.2 μM), showing
0.09 ± 0.02, 0.81 ± 0.08 and 0.8 ± 0.2 μM IC50 values, respect-
ively. On the cisplatin-resistant SKOV-3 cells, several com-
pounds (5d, 7a, 7b, 7d, 8b, 8c and 8d) exhibited lower activity
(IC50 > 30 μM) with respect to cisplatin whereas most of them
displayed a similar activity (IC50 = 3–8 μM). Remarkably, com-
pounds 4b, 5a, 5b, 6a, and 6d exhibited a higher activity on
SKOV-3 cells with respect to A2780 cells. Furthermore, complex
4d showed a very interesting activity on SKOV-3, exhibiting an
IC50 value (1.7 ± 0.9 μM) lower than that of cisplatin. The imid-
azolium salts 2a and 2b, also tested on the same cell models,
were completely inactive (data not shown) at the concen-
trations used on both cell lines (IC50 > 100 μM).
To test the selectivity of Pd-complexes versus cancer cells,
normal human fibroblasts (MRC-5) were treated with four
Fig. 2 Ellipsoid representation of 8d (B) crystal ASU contents (50%
probability).
Table 1 Eﬀects of the Pd-complexes on the proliferation of A2780 and
SKOV-3 cells. The inhibition of cell growth is denoted as IC50
IC50 (μM)
Complex A2780 (IC50) SKOV-3 (IC50)
Cisplatin 1.5 ± 0.2 5.94 ± 0.08
[Pd(μ-Cl)(η3-C3H5)]2 7.8 ± 0.2 10 ± 4
4a 4 ± 2 5.±1
4b 4 ± 2 3 ± 2
4c 0.09 ± 0.02 4.02 ± 0.09
4d 0.81 ± 0.08 1.7 ± 0.9
5a 7 ± 2 5.20 ± 0.08
5b 7.60 ± 0.07 6.5 ± 0.7
5d 0.8 ± 0.2 50.5 ± 0.5
6a 5 ± 2 4.0 ± 0.7
6b 3.72 ± 0.06 5.2 ± 0.9
6d 5 ± 1 3 ± 1
7a 80 ± 10 70 ± 10
7b 7 ± 2 40 ± 2
7d 9.2 ± 0.8 57 ± 8
8a 7 ± 2 7.7 ± 0.4
8b 4 ± 1 61 ± 7
8c 3.7 ± 0.5 60 ± 6
8d 6.3 ± 0.7 38 ± 6
Fig. 1 Ellipsoid representation of 4a (B) crystal ASU contents (50%
probability).
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diﬀerent compounds (4d, 5d, 6b, 8a) representative of diﬀerent
subclasses with high activity on cancer cells. As shown in
Table S1,† the compounds are almost inactive on fibroblasts,
suggesting a preferential activity on cancer cells. In particular,
the compound 4d is more active than 5d, 6b, and 8a on A2780
and SKOV3 cancer cell lines but with an IC50 > 100 μM on
fibroblasts.
Pro-apoptotic eﬀects on human A2780 and SKOV-3 cell lines
In order to examine whether the antiproliferative activity of the
analysed Pd-complexes is associated with induction of apopto-
sis, both A2780 and SKOV-3 cells were also evaluated employ-
ing the Annexin V release assay and a Muse cytometer (Merck
Millipore, Billerica, MA, USA), after treatment with two concen-
trations close to the IC50 values previously determined. The
found pro-apoptotic eﬀects are reported in Table 2, Fig. 3 and 4
(representative examples) and in Fig. 1A–E and 2A–E in the
ESI† (all results). In Table 2, the percentage of total apoptosis
is reported. Each data entry is compared to the analysis of
untreated cells (negative control, C−) in which the observed
total apoptosis was ≤5%.
On the A2780 cell line, the complexes that showed the
highest pro-apoptotic activity were 4c, 4d, 6b, 6d, 8b, 8c, and
8d, with total pro-apoptotic eﬀects between 21.00% (4d) and
98.35% (4c); in addition, complex 4c showed the greatest total
pro-apoptotic activity (54.04%) even with the lowest concen-
tration tested (0.1 μM). The remaining compounds were found
to be moderately or poorly active in inducing apoptosis on
this cisplatin-sensitive cell line, and the synthetic precursor
[Pd(μ-Cl)(η3-C3H5)]2 had a pro-apoptotic eﬀect on 29.40% of cells.
On the cisplatin-resistant SKOV-3 cell line, derivatives 4b,
4c, 4d, 5d, 6a, 6b, 6d, 7a, 7b, 7d, 8a, 8b, 8c, and 8d were found
to be particularly active, with total pro-apoptotic eﬀects
between 27.49% (5d) and 84.04% (4c). In particular, complex
4c showed the highest activity even at the lowest concentration
used (1 μM) with 43.78% of apoptotic cells. Table 2 also
reports the proportion of dead cells, suggesting that apoptotic
eﬀects and antiproliferative activity are not associated with
higher cytotoxicity.
Table 2 Pro-apoptotic eﬀects of the Pd-complexes on A2780 and SKOV-3 cell lines, detected at two diﬀerent concentrations (C−: untreated cells)
Complex Total apoptosis (%) Dead cells (%) Total apoptosis (%) Dead cells (%)
A2780 A2780 SKOV-3 SKOV-3
C− 2.61 1.96 5.30 0.50
Cisplatin 38.25 (2.5 μM) 3.30 (2.5 μM) 13.33 (5 μM) 1.17 (5 μM)
[Pd(μ-Cl)(η3-C3H5)]2 8.15 (1 μM) 2.00 (1 μM) 6.55 (1 μM) 0.55 (1 μM)
29.40 (10 μM) 1.00 (10 μM) 7.10 (10 μM) 2.20 (10 μM)
4a 3.80 (1 μM) 0.30 (1 μM) 6.35 (1 μM) 5.35 (1 μM)
12.35 (10 μM) 0.25 (10 μM) 12.71 (10 μM) 4.86 (10 μM)
4b 8.35 (1 μM) 0.50 (1 μM) 7.25 (1 μM) 8.05 (1 μM)
10.66 (10 μM) 0.33 (10 μM) 44.31 (10 μM) 1.12 (10 μM)
4c 54.04 (0.1 μM) 0.25 (0.1 μM) 43.78 (1 μM) 15.83 (0.1 μM)
98.35 (1 μM) 0.24 (1 μM) 84.04 (10 μM) 3.16 (1 μM)
4d 2.25 (1 μM) 7.62 (1 μM) 6.50 (0.5 μM) 3.70 (1 μM)
21.00 (10 μM) 1.45 (10 μM) 52.35 (5 μM) 0.57 (10 μM)
5a 3.00 (1 μM) 0.30 (1 μM) 2.45 (1 μM) 0.10 (1 μM)
15.25 (10 μM) 0.00 (10 μM) 3.10 (10 μM) 0.65 (10 μM)
5b 4.25 (1 μM) 0.80 (1 μM) 3.00 (1 μM) 0.45 (1 μM)
7.05 (10 μM) 0.15 (10 μM) 3.65 (10 μM) 0.65 (10 μM)
5d 5.49 (1 μM) 2.32 (1 μM) 9.82 (50 μM) 3.06 (1 μM)
5.76 (10 μM) 1.43 (10 μM) 27.49 (100 μM) 1.71 (10 μM)
6a 9.50 (1 μM) 0.60 (1 μM) 15.05 (1 μM) 0.60 (1 μM)
9.20 (10 μM) 0.15 (10 μM) 34.55 (10 μM) 0.15 (10 μM)
6b 26.52 (1 μM) 0.59 (1 μM) 6.26 (1 μM) 0.59 (1 μM)
61.18 (10 μM) 0.18 (10 μM) 69.10 (10 μM) 0.18 (10 μM)
6d 1.40 (1 μM) 8.92 (1 μM) 3.45 (1 μM) 0.90 (1 μM)
79.45 (10 μM) 0.34 (10 μM) 52.95 (10 μM) 0.15 (10 μM)
7a 3.20 (50 μM) 2.10 (50 μM) 12.55 (50 μM) 0.36 (50 μM)
2.21 (100 μM) 1.31 (100 μM) 44.96 (100 μM) 0.29 (100 μM)
7b 2.66 (1 μM) 2.26 (1 μM) 11.25 (25 μM) 0.15 (1 μM)
1.60 (10 μM) 1.30 (10 μM) 53.01 (50 μM) 0.25 (10 μM)
7d 2.97 (1 μM) 0.86 (1 μM) 8.73 (50 μM) 0.51 (1 μM)
5.65 (10 μM) 0.96 (10 μM) 36.37 (100 μM) 0.34 (10 μM)
8a 2.65 (1 μM) 0.20 (1 μM) 3.65 (1 μM) 0.35 (1 μM)
3.50 (10 μM) 0.25 (10 μM) 30.89 (10 μM) 0.46 (10 μM)
8b 5.69 (1 μM) 1.86 (1 μM) 6.32 (50 μM) 0.41 (1 μM)
43.03 (10 μM) 0.34 (10 μM) 56.60 (100 μM) 0.44 (10 μM)
8c 1.39 (1 μM) 7.28 (1 μM) 7.84 (50 μM) 0.39 (1 μM)
23.66 (10 μM) 3.09 (10 μM) 52.01 (100 μM) 0.38 (10 μM)
8d 5.90 (1 μM) 0.56 (1 μM) 12.74 (25 μM) 1.29 (1 μM)
61.17 (10 μM) 0.00 (10 μM) 79.32 (50 μM) 3.18 (10 μM)
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Conclusions
In this contribution we have proposed a complete and opti-
mised protocol for the synthesis of new cationic allyl palla-
dium complexes bearing NHC ligands with a purinic frame-
work. The combination of the palladium-allyl organometallic
function with the natural imprint of the spectator ligand
seems to play a crucial role in promoting the cytotoxic pro-
perties of these compounds. Their antiproliferative activity has
been tested in vitro on cisplatin-sensitive A2780 and cisplatin-
Fig. 3 Representative apoptosis proﬁles of A2780 cells untreated (C−), treated with cisplatin (C+) and treated with complexes 4c, 6d and 8b
(110 μM) for 72 h.
Fig. 4 Representative apoptosis proﬁles of SKOV-3 cells untreated (C−), treated with cisplatin (C+) and treated with complexes 4c, 6d and 8b
(1–10 μM) for 72 h.
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resistant SKOV-3 cell lines and compared with cisplatin as an
etalon drug. Complexes 4c, 4d, and 5d (for A2780 cells) and 4d
(for SKOV-3 cells) displayed higher antiproliferative eﬀects
than cisplatin, showing that the simultaneous coordination of
one triphenylphosphine and one N-heterocyclic carbene on
the palladium allyl fragment represents the most promising
configuration. However, the most active compounds on cancer
cells are almost inactive on normal cells, suggesting a marked
cancer selectivity.
Moreover, it was proved that the anti-proliferative activity of
many of the synthesized complexes is associated with induc-
tion of apoptosis. No major cytotoxicity was observed after
evaluation of the proportion of dead cells (Table 2).
Despite the fact that our data do not clarify the molecular
target(s) of the compounds presented here, the apoptosis
network should be considered as a major cellular target.
A future extension of this first encouraging study will have as
its main goals the identification of the true molecular target of
these allyl palladium complexes and the definition of their
mode of action. As a further possible application these com-
pounds might be considered for combined antitumor therapy
after co-administration with pro-apoptotic molecules exhibiting
a verified mechanism of action (paclitaxel, topotecan, doxo-
rubicin, etoposide, or gemcitabine, or with antineoplastic mole-
cules displaying diﬀerent mechanisms of action).33–41 A recog-
nized advantage of the combined antitumor approach is the
expected fewer side eﬀects associated with the use of minor con-
centrations. In any case, in vivo activity of the most eﬃcient
compounds studied here would clarify whether the described
eﬀects on tumor cell lines is accompanied by the absence of
side eﬀects on normal cells and networks. Only in this case
these complexes might be further considered for possible bio-
medical application in the field of anticancer treatment.
Experimental
All the synthesis of the complexes were carried out using stan-
dard Schlenk techniques under an atmosphere of dry nitrogen.
Solvents were dried and distilled according to standard
methods: CH2Cl2 was first treated with 3 Å molecular sieves
and then distilled over P2O5; CH3CN was distilled over CaH2
and stored over 3 Å molecular sieves. All the other chemicals
were commercially available grade products and were used as
purchased.
Complexes 3a, 3b, and 3d and complexes 7a, 7b, and 7d
were synthesized according to the procedure described in a
previous study.19
The IR, 1H, 13C and 31P NMR spectra were recorded on a
PerkinElmer Spectrum One spectrophotometer and a Bruker
300 or 400 MHz Avance spectrometer, respectively.
Elemental analysis was carried out using an Elemental
CHN “CUBO Micro Vario” analyzer.
ESI-MS analyses were performed using a LCQ-Duo (Thermo
Finnigan) operating in the positive ion mode. Instrumental
parameters: capillary voltage 10 V, spray voltage 4.5 kV, capil-
lary temperature 200 °C, mass scan range 150 to 2000 amu, N2
was used as the sheath gas and the He pressure inside the trap
was kept constant.
The pressure directly read by an ion gauge (in the absence
of a N2 stream) was 1.33 × 10
−5 Torr. Sample solutions were
prepared by dissolving the compounds in acetonitrile and
directly infusing into the ESI source with a syringe pump at
8 µL min−1 flow rate.
General procedure for the synthesis of alkyl-functionalized
caﬀeine, theophylline and theobromine (1)
5.55 mmol (ca. 1 g) of the starting xanthine (theophylline or
theobromine) and 1.15 g (8.33 mmol) of K2CO3 were sus-
pended in 20 mL of DMF. Two equivalents (11.1 mmol) of the
appropriate alkyl halide were added to the suspension and the
resulting mixture was vigorously stirred overnight at R.T.
Finally, the compounds were precipitated by the addition of
H2O (ca. 100 mL).
7-Benzyl-1,3-dimethylxanthine (1b)
White solid, yield 93%.
1H-NMR (400 MHz, CDCl3, T = 298 K, ppm) δ: 3.43 (s, 3H,
N–CH3), 3.60 (s, 3H, N–CH3), 5.52 (s, 2H, N–CH2), 7.30–7.40
(m, 5H, Ph), 7.58 (s, 1H, NCHN). 13C{1H}-NMR (CDCl3, T =
298 K, ppm) δ: 28.0 (N–CH3), 29.8 (N–CH3), 50.3 (N–CH2),
107.0 (C5), 128.0, 128.7, 129.1, 135.4 (CPh), 140.9 (N–CH–N),
148.9 (C4), 151.7 (CvO), 155.3 (CvO).
ESI-MS (CH3CN): m/z calcd for C14H15N4O2 [M + H]
+ 271.12;
found: 271.06.
Anal. calcd for C14H14N4O2: C 62.21, H 5.22, N 20.73.
Found: C 62.32, H 5.14, N 20.64.
7-Phenylpropargyl-1,3-dimethylxanthine (1c)
Pink solid, yield 95%.
1H-NMR (400 MHz, CDCl3, T = 298 K, ppm) δ: 3.45 (s, 3H,
N–CH3), 3.63 (s, 3H, N–CH3), 5.42 (s, 2H, N–CH2), 7.32–7.50
(m, 5H, Ph), 7.94 (s, 1H, NCHN).
13C{1H}-NMR (CDCl3, T = 298 K, ppm) δ: 28.0 (N–CH3), 29.8
(N–CH3), 37.4 (N–CH2), 80.5 (uC̲–CH2), 87.6 (uC ̲–Ph), 106.8
(C5), 121.5, 128.5, 129.2, 131.9 (CPh), 140.6 (N–CH–N), 148.9
(C4), 151.7 (CvO), 155.3 (CvO).
ESI-MS (CH3CN): m/z calcd for C16H15N4O2 [M + H]
+ 295.12;
found: 294.98.
Anal. calcd for C16H14N4O2: C 65.30, H 4.79, N 19.04.
Found: C 65.49, H 4.83, N 18.89.
1-Benzyl-3,7-dimethylxanthine (1d)
White solid, yield 95%.
1H-NMR (400 MHz, CDCl3, T = 298 K, ppm) δ: 3.59 (s, 3H,
N–CH3), 4.00 (s, 3H, N–CH3), 5.22 (s, 2H, N–CH2), 7.25–7.55
(m, 5H, Ph), 7.51 (s, 1H, NCHN). 13C{1H}-NMR (CDCl3, T =
298 K, ppm) δ: 29.8 (N–CH3), 33.6 (N–CH3), 44.5 (N–CH2),
107.7 (C5), 127.5, 128.4, 128.8, 137.3 (CPh), 141.5 (N–CH–N),
148.9 (C4), 151.6 (CvO), 155.3 (CvO).
ESI-MS (CH3CN): m/z calcd for C14H15N4O2 [M + H]
+ 271.12;
found: 271.14.
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Anal. calcd for C14H14N4O2: C 62.21, H 5.22, N 20.73.
Found: C 62.45, H 5.07, N 20.99.
General procedure for the synthesis of the imidazolium salts
from functionalized theophylline and theobromine (2)
Into a 50 mL flask, 1.8 mmol of functionalized xanthine (1a–d
where 1a = commercial caﬀeine) were dissolved in ca. 25 mL of
CH3CN. After the addition of one equivalent (1.8 mmol) of
Me3OBF4 the resulting solution was vigorously stirred for
5 min and then 100 mg of Na2CO3 were added to the mixture,
which was stirred for 45 min. Further addition of 0.6 equi-
valent (1.1 mmol) of Me3OBF4 and 10 min of additional stir-
ring led to virtual completion. The excess of base Na2CO3 and
the NaBF4 formed were filtered oﬀ and the solvent was comple-
tely removed under reduced pressure. The solid was washed
with three aliquots of a 2 : 1 mixture of Et2O/CH2Cl2 on a sin-
tered glass filter, dried under vacuum and characterized.
1,3,7,9-Tetramethylxanthinium tetrafluoroborate (2a)
White solid, yield 97%, m.p. = 132–133 °C.
1H-NMR (400 MHz, CD3CN, T = 298 K, ppm) δ: 3.35 (s, 3H,
N–CH3), 3.74 (s, 3H, N–CH3), 4.08 (s, 6H, 2N–CH3), 8.47 (s, 1H,
NCHN). 13C{1H}-NMR (CD3CN, T = 298 K, ppm) δ: 28.7
(N–CH3), 31.8 (N–CH3), 36.3 (N–CH3), 37.6 (N–CH3), 109.1 (C
5),
139.3 (N–CH–N), 140.2 (C4), 151.1 (CvO), 154.2 (CvO).
ESI-MS (CH3CN): m/z calcd for C9H13N4O2 [M]
+ 209.10;
found: 209.07.
Anal. calcd for C9H13BF4N4O2: C 36.52, H 4.43, N 18.93.
Found: C 36.74, H 4.61, N 18.88.
7-Benzyl-1,3,9-trimethylxanthinium tetrafluoroborate (2b)
White solid, yield 91%, m.p. = 251–253 °C.
1H-NMR (400 MHz, CD3CN, T = 298 K, ppm) δ: 3.33 (s, 3H,
N–CH3), 3.73 (s, 3H, N–CH3), 4.06 (s, 3H, N–CH3), 5.70 (s, 2H,
N–CH2), 7.45–7.48 (m, 5H, Ph), 8.56 (s, 1H, NCHN).
13C{1H}-
NMR (CD3CN, T = 298 K, ppm) δ: 28.8 (N–CH3), 31.8 (N–CH3),
37.9 (N–CH3), 52.7 (N–CH2), 108.4 (C
5), 129.2, 129.7, 129.8,
133.9 (CPh), 138.9 (N–CH–N), 140.6 (C
4), 151.0 (CvO), 154.0
(CvO).
ESI-MS (CH3CN): m/z calcd for C15H17N4O2 [M]
+ 285.13;
found: 285.04.
Anal. calcd for C15H17BF4N4O2: C 48.41, H 4.60, N 15.06.
Found: C 48.39, H 4.64, N 15.18.
7-Phenylpropargyl-1,3,9-trimethylxanthinium tetrafluoroborate
(2c)
White solid, yield 92% (612 mg), m.p. = 231 dec. °C.
1H-NMR (400 MHz, CD3CN, T = 298 K, ppm) δ: 3.37 (s, 3H,
N–CH3), 3.76 (s, 3H, N–CH3), 4.14 (s, 3H, N–CH3), 5.57 (s, 2H,
N–CH2), 7.42–7.60 (m, 5H, Ph), 8.85 (s, 1H, NCHN).
13C{1H}-
NMR (CD3CN, T = 298 K, ppm) δ: 28.8 (N–CH3), 31.9 (N–CH3),
37.9 (N–CH3), 40.7 (N–CH2), 79.2 (uC̲–CH2), 89.4 (uC̲–Ph),
108.3 (C5), 121.6, 129.4, 130.4, 132.5 (CPh), 138.8 (N–CH–N),
140.6 (C4), 151.0 (CvO), 154.0 (CvO).
ESI-MS (CH3CN): m/z calcd for C17H17N4O2 [M]
+ 309.13;
found: 309.02.
Anal. calcd for C17H17BF4N4O2: C 51.54, H 4.33, N 14.14.
Found: C 51.73, H 4.28, N 14.31.
1-Benzyl-3,7,9-trimethylxanthinium tetrafluoroborate (2d)
White solid, yield 94% (621 mg), m.p. = 171–172 °C.
1H-NMR (400 MHz, CD3CN, T = 298 K, ppm) δ: 3.74 (s, 3H,
N–CH3), 4.08 (s, 3H, N–CH3), 4.09 (s, 3H, N–CH3), 5.17 (s, 2H,
N–CH2), 7.28–7.42 (m, 5H, Ph), 8.48 (s, 1H, NCHN).
13C{1H}-
NMR (CD3CN, T = 298 K, ppm) δ: 31.9 (N–CH3), 36.4 (N–CH3),
37.6 (N–CH3), 45.6 (N–CH2), 109.2 (C
5), 128.3, 128.6, 129.1,
137.1 (CPh), 139.4 (N–CH–N), 140.5 (C
4), 151.0 (CvO), 154.1
(CvO).
ESI-MS (CH3CN): m/z calcd for C15H17N4O2 [M]
+ 285.13;
found: 285.11.
Anal. calcd for C15H17BF4N4O2: C 48.41, H 4.60, N 15.06.
Found: C 48.65, H 4.72, N 15.14.
Preparation of a 1 : 1 mixture of 3c and AgBF4
0.1130 g (0.2852 mmol) of the imidazolium salt 2c was dis-
solved in 30 mL of anhydrous CH3CN in a 100 mL two necked
flask and 0.09364 g (0.1571 mmol) of Ag2O was added under
an inert atmosphere (Ar).
The mixture was stirred for 24 h at R.T. in the dark. The
solution was filtered on a Millipore membrane filter in order
to remove excess Ag2O. The resulting clear solution was con-
centrated under vacuum and the title complex was precipitated
by the addition of diethyl ether. The white complex was separ-
ated by filtration and repeatedly washed with diethyl ether and
n-pentane and finally dried under vacuum.
0.1305 g (yield 91%) of a 1 : 1 mixture of 3c and AgBF4 was
obtained.
1H-NMR (400 MHz, CD3CN, T = 298 K, ppm) δ: 3.35 (s, 6H,
2NCH3), 3.70 (s, 6H, 2NCH3), 4.03 (s, 6H, 2NCH3), 5.40 (s, 4H,
2NCH2), 7.27–7.43 (m, 10H, 2Ph).
13C{1H}-NMR (CD3CN, T =
298 K, ppm) δ: 27.9 (CH3, NCH3), 31.4 (CH3, NCH3), 40.1 (CH2,
NCH2), 40.2 (CH3, NCH3), 82.5 (C, CH2–C̲u), 88.7 (C, Ph–C̲u),
108.7 (C, C5), 121.3–131.8 (Ph), 140.4 (C, C4), 150.7 (C, CvO),
153.5 (C, CvO), 187.1 (C, carbene).
IR (KBr): νCuC = 2218 cm
−1, νCO = 1710, 1668 cm
−1, νBF =
1054 cm−1.
Anal. calcd for C34H32Ag2B2F8N8O4: C 40.59, H 3.21,
N 11.14. Found: C 40.82, H 3.04, N 11.35.
Synthesis of complex 4a
0.0195 g (0.053 mmol) of the dimer [Pd(μ-Cl)(η3-C3H5)]2 and
0.0279 g (0.106 mmol) of PPh3 were dissolved in ca. 20 mL of
anhydrous CH3CN in a 50 mL two necked flask under an inert
atmosphere (Ar). The resulting mixture was treated with
0.0388 g (0.048 mmol) of 3a/AgBF4 and stirred at RT for ca.
15 min.
The precipitated AgCl was removed by filtration on a
Millipore membrane filter.
Addition of diethyl ether to the concentrated solution
yielded the precipitation of complex 4a as a yellow solid, which
was filtered oﬀ on a Gooch and washed with n-pentane.
0.0576 g of 4a was obtained (yield 85%).
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1H-NMR (400 MHz, T = 298 K, CDCl3, ppm) δ: 3.16 (d, 1H,
J = 13.4 Hz, anti allyl-H trans C), 3.26 (d, 1H, J = 13.7 Hz, anti
allyl-H trans C), 3.27 (m, 1H, anti allyl-H trans P), 3.38 (s, 6H,
2NCH3), 3.59 (s, 6H, 2NCH3), 3.61 (s, 6H, 2NCH3), 3.68 (m, 1H,
anti allyl-H trans P), 3.76 (s, 3H, NCH3), 3.78 (s, 3H, NCH3),
4.11 (d, 1H, J = 8.4 Hz, syn allyl-H trans C), 4.19 (d, 1H, J =
7.6 Hz, syn allyl-H trans C), 4.59 (dd, 1H, JH–H = JH–P = 5.9 Hz,
syn allyl-H trans P), 4.80 (dt, 1H, JH–H = JH–P = 6.6 Hz, syn allyl-
H trans P), 5.71 (m, 1H, central allyl-H), 5.99 (m, 1H, central
allyl-H), 7.25–7.53 (m, 30H, 6Ph). 13C{1H}-NMR (T = 298 K,
CDCl3, ppm) δ: 28.6 (CH3, NCH3), 31.7 (CH3, NCH3), 36.9
(CH3, NCH3), 37.1 (CH3, NCH3), 38.7 (CH3, NCH3), 38.9 (CH3,
NCH3), 68.5 (d, CH2, JC–P = 28.5 Hz, allyl trans P), 69.3 (d, CH2,
JC–P = 27.6 Hz, allyl trans P), 69.4 (d, CH2, JC–P = 1.8 Hz, allyl
trans C), 69.4 (d, CH2, JC–P = 1.7 Hz, allyl trans C), 110.4 (C, C
5),
110.6 (C, C5), 121.4 (d, CH, JC–P = 5.4 Hz, central allyl), 122.8
(d, CH, JC–P = 5.1 Hz, central allyl), 129.2–133.2 (Ph), 141.0
(C, C4), 141.1 (C, C4), 150.4 (C, CvO), 153.0 (C, CvO), 185.8
(d, C, JC–P = 19.7 Hz, carbene), 186.2 (d, C, JC–P = 19.3 Hz,
carbene). 31P{1H}-NMR (T = 298 K, CDCl3, ppm) δ: 25.9, 25.8.
IR (KBr): νCO = 1709, 1668 cm
−1, νBF = 1059 cm
−1.
Anal. calcd for C30H32BF4N4O2PPd: C 51.12, H 4.58, N 7.95.
Found: C 51.42, H 4.32, N 8.10.
Synthesis of complex 4b
Complex 4b was prepared in an analogous manner to that
described for 4a starting from 0.0144 g of [Pd(μ-Cl)(η3-allyl)]2,
0.0358 g of 3b/AgBF4 and 0.0196 g of PPh3.
0.0511 g (yield 88%) of 4b was obtained.
1H-NMR (400 MHz, T = 298 K, CDCl3, ppm) δ: 2.38 (m, 1H,
anti allyl-H trans P), 2.93 (d, 1H, J = 13.6 Hz, anti allyl-H trans
C), 3.17 (d, 1H, J = 13.4 Hz, anti allyl-H trans C), 3.40 (s, 3H,
NCH3), 3.42 (s, 3H, NCH3), 3.60 (m, 1H, anti allyl-H trans P),
3.62 (s, 3H, NCH3), 3.63 (s, 3H, NCH3), 3.86 (s, 3H, NCH3),
3.96 (dd, 1H, JH–H = 6.8 Hz, JH–P = 6.8 Hz, syn allyl-H trans P),
4.09 (d, 1H, J = 6.4 Hz, syn allyl-H trans C), 4.19 (d, 1H, J =
6.1 Hz, syn allyl-H trans C), 4.70 (dd, 1H, JH–H = 7.7 Hz, JH–P =
7.7 Hz, syn allyl-H trans P), 4.80 and 5.57 (AB system, 2H, J =
14.8 Hz, NCH2), 5.03 and 5.63 (AB system, 2H, J = 15.0 Hz,
NCH2), 5.22 (m, 1H, central allyl-H), 5.97 (m, 1H, central allyl-H),
7.00–7.60 (m, 40H, 8Ph).
13C{1H}-NMR (T = 298 K, CDCl3, ppm) δ: 28.7 (CH3, NCH3),
28.8 (CH3, NCH3), 31.9 (CH3, NCH3), 39.3 (CH3, NCH3), 39.5
(CH3, NCH3), 52.4 (CH2, NCH2), 52.7 (CH2, NCH2), 68.6
(d, CH2, JC–P = 1.9 Hz, allyl trans-C), 68.7 (d, CH2, JC–P = 1.8 Hz,
allyl trans-C), 70.1 (d, CH2, JC–P = 27.7 Hz, allyl trans-P), 70.8 (d,
CH2, JC–P = 27.8 Hz, allyl trans-P), 110.1 (C, C
5), 110.3 (C, C5),
121.0 (CH, central allyl), 122.8 (CH, central allyl), 127.2–135.3
(Ph), 141.1 (C4), 141.3 (C4), 143.7 (Ph), 150.3 (C, CvO), 150.4
(C, CvO), 152.8 (C, CvO), 152.9 (C, CvO), 187.5 (d, C, JC–P =
18.5 Hz, carbene), 187.8 (d, C, JC–P = 18.4 Hz, carbene).
31P{1H}-NMR (T = 298 K, CDCl3, ppm) δ: 25.6, 26.3.
IR (KBr): νCO = 1709, 1668 cm
−1, νBF = 1056 cm
−1.
Anal. calcd for C36H36BF4N4O2PPd: C 55.37, H 4.65, N 7.17.
Found: C 55.12, H 4.80, N 7.38.
Synthesis of complex 4c
Complex 4c was prepared in an analogous manner to that
described for 4a starting from 0.0160 g of [Pd(μ-Cl)(η3-allyl)]2,
0.0418 g of 3c/AgBF4 and 0.0218 g of PPh3.
0.0559 g (yield 84%) of 4c was obtained.
1H-NMR (400 MHz, T = 298 K, CDCl3, ppm) δ: 2.97 (d, 1H,
J = 13.3 Hz, anti allyl-H trans C), 3.20 (d, 1H, J = 12.8 Hz, anti
allyl-H trans C), 3.36 (m, 1H, anti allyl-H trans P), 3.42 (s, 6H,
2NCH3), 3.61 (s, 3H, NCH3), 3.62 (s, 3H, NCH3), 3.68 (s, 3H,
NCH3), 3.76 (m, 1H, anti allyl-H trans P), 3.82 (s, 3H, NCH3),
4.04 (d, 1H, J = 6.1 Hz, syn allyl-H trans C), 4.22 (d, 1H, J =
6.4 Hz, syn allyl-H trans C), 4.71 (dd, 1H, JH–H = 6.0 Hz, JH–P =
6.8 Hz, syn allyl-H trans P), 4.82 and 5.28 (AB system, 2H, J =
17.2 Hz, NCH2), 4.88 and 5.47 (AB system, 2H, J = 17.6 Hz,
NCH2), 4.89 (m, 1H, syn allyl-H trans P), 5.63 (m, 1H, central
allyl-H), 6.03 (m, 2H, central allyl-H), 7.15–7.46 (m, 40H, 8Ph).
13C{1H}-NMR (T = 298 K, CDCl3, ppm) δ: 28.7 (CH3, NCH3),
31.8 (CH3, NCH3), 39.4 (CH3, NCH3), 40.0 (CH2, NCH2), 68.9
(CH2, allyl trans-C), 69.3 (CH2, allyl trans-C), 69.9 (d, CH2,
JC–P = 27.5 Hz, allyl trans-P), 70.4 (d, CH2, JC–P = 27.6 Hz, allyl
trans-P), 81.6 (C, uC̲–CH2), 81.9 (C, uC̲–CH2), 86.5 (C,
uC̲–Ph), 87.4 (C, uC̲–Ph), 109.6 (C, C5), 109.7 (C, C5), 121.4
(d, CH, JC–P = 5.1 Hz, central allyl), 122.7 (d, CH, JC–P = 5.2 Hz,
central allyl), 128.4–134.0 (Ph), 141.2 (C, C4), 150.4 (C, CvO),
152.6 (C, CvO), 152.7 (C, CvO), 187.3 (d, C, JC–P = 18.8 Hz,
carbene), 187.7 (d, C, JC–P = 18.5 Hz, carbene).
31P{1H}-NMR
(T = 298 K, CDCl3, ppm) δ: 25.4, 25.9.
IR (KBr): νCO = 1709, 1667 cm
−1, νBF = 1058 cm
−1.
Anal. calcd for C38H36BF4N4O2PPd: C 56.70, H 4.51, N 6.96.
Found: C 56.52, H 4.78, N 7.12.
Synthesis of complex 4d
Complex 4d was prepared in an analogous manner to that
described for 4a starting from 0.0154 g of [Pd(μ-Cl)(η3-allyl)]2,
0.0383 g of 3d/AgBF4 and 0.0210 g of PPh3.
0.0522 g (yield 84%) of 4d was obtained.
1H-NMR (400 MHz, T = 298 K, CDCl3, ppm) δ: 3.13 (d, 1H,
J = 13.4 Hz, anti allyl-H trans C), 3.28 (d + m, 2H, J = 13.2 Hz,
anti allyl-H trans C), 3.29 (m, 1H, anti allyl-H trans P), 3.58 (s,
3H, NCH3), 3.59 (s, 3H, NCH3), 3.60 (s, 3H, NCH3), 3.62 (s, 3H,
NCH3), 3.68 (m, 1H, anti allyl-H trans P), 3.74 (s, 3H, NCH3),
3.81 (s, 3H, NCH3), 4.13 (d, 1H, J = 7.4 Hz, syn allyl-H trans C),
4.21 (d, 1H, J = 7.8 Hz, syn allyl-H trans C), 4.58 (dd, 1H, JH–H =
JH–P = 5.2 Hz, syn allyl-H trans P), 4.79 (dd, 1H, JH–H = 5.5 Hz,
JH–P = 5.5 Hz, syn allyl-H trans P), 5.15 (s, 4H, 2 NCH2), 5.70
(m, 1H, central allyl-H), 5.99 (m, 1H, central allyl-H), 7.25–7.47
(m, 40H, 8Ph). 13C{1H}-NMR (T = 298 K, CDCl3, ppm) δ: 31.8
(CH3, NCH3), 36.9 (CH3, NCH3), 37.0 (CH3, NCH3), 38.7 (CH3,
NCH3), 38.9 (CH3, NCH3), 45.1 (CH2, NCH2), 68.3 (d, CH2,
JC–P = 28.4 Hz, allyl trans-P), 69.1 (d, CH2, JC–P = 28.1 Hz, allyl
trans-P), 69.2 (d, CH2, JC–P = 1.7 Hz, allyl trans-C), 69.4 (d, CH2,
JC–P = 1.9 Hz, allyl trans-C), 110.7 (C, C
5), 121.3 (d, CH, JC–P =
5.5 Hz, central allyl), 122.8 (d, CH, JC–P = 5.3 Hz, central allyl),
127.9–136.4 (Ph), 141.0 (C, C4), 141.1 (C, C4), 150.2 (C, CvO),
152.7 (C, CvO), 186.1 (d, C, JC–P = 19.3 Hz, carbene), 186.5 (d,
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C, JC–P = 19.4 Hz, carbene).
31P{1H}-NMR (T = 298 K, CDCl3,
ppm) δ: 25.9, 26.0.
IR (KBr): νCO = 1707, 1668 cm
−1, νBF = 1056 cm
−1.
Anal. calcd for C36H36BF4N4O2PPd: C 55.37, H 4.65, N 7.17.
Found: C 55.22, H 4.58, N 7.42.
Synthesis of complex 5a
0.0411 g (0.112 mmol) of the dimer [Pd(μ-Cl)(η3-C3H5)]2 and
0.0353 g (0.224 mmol) of PTA (1,3,5-triaza-7-phosphadaman-
tane) were dissolved in ca. 30 mL of anhydrous CH3CN in a
100 mL two necked flask under an inert atmosphere (Ar). The
resulting mixture was treated with 0.0787 g (0.0975 mmol) of
3a/AgBF4 and stirred at RT for ca. 1 hour.
The precipitated AgCl was removed by filtration on a
Millipore membrane filter.
The solution was dried under vacuum and the residue was
treated with 2 mL of CH2Cl2.
Addition of diethyl ether to the concentrated solution
yielded the precipitation of complex 5a as a brownish solid,
which was filtered oﬀ on a Gooch, washed with n-pentane and
dried under vacuum.
0.0991 g of 5a was obtained (yield 97%).
1H-NMR (400 MHz, T = 298 K, D2O, ppm) δ: 2.88 (d, 2H, J =
13.2 Hz, 2 anti allyl-H trans-C), 3.15 (m, 2H, 2 anti allyl-H trans-P),
3.32 (s, 3H, NCH3), 3.33 (s, 3H, NCH3), 3.74 (s, 3H, NCH3),
3.77 (s, 3H, NCH3), 3.80 (s, 3H, NCH3), 3.87 (s, 3H, NCH3),
3.92 (s, 3H, NCH3), 4.05 (s, 3H, NCH3), 4.21 (s, 12H,
6 NCH2PPTA), 4.38 (d, 2H, J = 7.4 Hz, 2 syn allyl-H trans-C), 4.47
(m, 2H, 2 syn allyl-H trans-P), 4.55 (m, 12H, 6 NCH2NPTA), 5.48
(m, 2H, 2 central allyl-H). 13C{1H}-NMR (T = 298 K, D2O, ppm)
δ: 28.4 (CH3, NCH3), 31.8 (CH3, NCH3), 36.7 (CH3, NCH3), 36.9
(CH3, NCH3), 38.2 (CH3, NCH3), 38.4 (CH3, NCH3), 50.3 (CH2,
NCH2P, JC–P = 13.6 Hz), 62.7 (CH2, allyl trans-C), 62.8 (CH2,
allyl trans-C), 68.9 (d, CH2, JC–P = 4.8 Hz, allyl trans-P), 69.2 (d,
CH2, JC–P = 5.2 Hz, allyl trans-P), 70.7 (CH2, NCH2N), 70.8
(CH2, NCH2N), 111.2 (C, C
5), 111.4 (C, C5), 121.9 (CH, central
allyl), 122.0 (CH, central allyl), 141.8 (C, C4), 141.9 (C, C4),
151.8 (C, CvO), 154.5 (C, CvO), 183.9 (C, JC–P = 21.2 Hz,
carbene). 31P{1H}-NMR (T = 298 K, D2O, ppm) δ: −52.4.
IR (KBr): νCO = 1704, 1665 cm
−1, νBF = 1031, 1084 cm
−1.
Anal. calcd for C18H29BF4N7O2PPd: C 36.05, H 4.87,
N 16.35. Found: C 36.34, H 4.97, N 16.14.
Synthesis of complex 5b
Complex 5b was prepared in an analogous manner to that
described for 5a starting from 0.0353 g of [Pd(μ-Cl)(η3-allyl)]2,
0.0804 g of 3b/AgBF4 and 0.0304 g of PTA.
0.0925 g (yield 82%) of 5b was obtained.
1H-NMR (400 MHz, T = 298 K, D2O, ppm) δ: 2.76 (m, 2H,
2 anti allyl-H trans-C), 3.06 (m, 2H, 2 anti allyl-H trans-P), 3.28
(s, 3H, NCH3), 3.29 (s, 3H, NCH3), 3.72 (s, 6H, 3 NCH2PPTA),
3.75 (s, 6H, 3 NCH2PPTA), 3.77 (s, 3H, NCH3), 3.80 (s, 3H,
NCH3), 3.88 (s, 3H, NCH3), 4.06 (s, 3H, NCH3), 4.27–4.70 (m,
16 H, 6 NCH2NPTA and 2 syn allyl-H trans-C and 2 syn allyl-H
trans-P), 5.07 and 5.64 (AB system, 2H, J = 15.4 Hz, NCH2), 5.29
and 5.76 (AB system, 2H, J = 15.7 Hz, NCH2), 5.36 (m, 2H,
2 central allyl-H), 6.81–7.36 (m, 10H, 2Ph). 13C{1H}-NMR (T =
298 K, D2O, ppm) δ: 28.5 (CH3, NCH3), 31.9 (CH3, NCH3), 38.6
(CH3, NCH3), 38.9 (CH3, NCH3), 49.9 (d, CH2, J = 13.5 Hz,
NCH2P), 50.0 (d, CH2, J = 13.6 Hz, NCH2P), 52.5 (CH2, NCH2),
52.7 (CH2, NCH2), 62.6 (CH2, allyl trans-C), 63.0 (CH2, allyl
trans-C), 69.4 (d, CH2, JC–P = 26.7 Hz, allyl trans-P), 69.9 (d,
CH2, JC–P = 27.8 Hz, allyl trans-P), 70.4 (CH2, NCH2NPTA) 70.5
(CH2, NCH2N), 111.1 (C, C
5), 111.4 (C, C5), 121.9 (CH, central
allyl), 126.9–136.7 (Ph), 141.8 (C, C4), 141.9 (C, C4), 151.8 (C,
CvO), 154.2 (C, CvO), 186.0 (d, C, JC–P = 20.4, carbene), 186.1
(d, C, JC–P = 20.5 Hz, carbene).
31P{1H}-NMR (T = 298 K, D2O,
ppm) δ: −54.1, −54.0.
IR (KBr): νCO = 1705, 1664 cm
−1, νBF = 1035, 1083 cm
−1.
Anal. calcd for C24H33BF4N7O2PPd: C 42.66, H 4.92,
N 14.51. Found: C 42.82, H 4.78, N 14.22.
Synthesis of complex 5d
Complex 5d was prepared in an analogous manner to that
described for 5a starting from 0.0352 g of [Pd(μ-Cl)(η3-allyl)]2,
0.0800 g of 3d/AgBF4 and 0.0301 g of PTA.
0.1057 g (yield 94%) of 5d was obtained.
1H-NMR (400 MHz, T = 298 K, D2O, ppm) δ: 2.83 (d, J =
13.8 Hz, 2H, 2 anti allyl-H trans-C), 3.07 (m, 2H, 2 anti allyl-H
trans-P), 3.69 (s, 3H, NCH3), 3.70 (s, 3H, NCH3), 3.73 (s, 3H,
NCH3), 3.82 (s, 3H, NCH3), 3.87 (s, 3H, NCH3), 4.01 (s, 3H,
NCH3), 4.15 (s, 6H, 3 NCH2PPTA), 4.27 (s, 6H, 3 NCH2PPTA), 4.32
(d, J = 6.6 Hz, 2H, 2 syn allyl-H trans-C), 4.45 (m, 2H, 2 syn allyl-H
trans-P), 4.50–4.70 (m, 12H, 6 NCH2PPTA), 5.10 (2s, 4H, 2 N-CH2),
5.42 (m, 2H, 2 central allyl-H), 7.25–7.30 (m, 10H, 2Ph).
13C{1H}-NMR (T = 298 K, D2O, ppm) δ: 31.9 (CH3, NCH3),
36.8 (CH3, NCH3), 37.1 (CH3, NCH3), 38.2 (CH3, NCH3), 38.5
(CH3, NCH3), 45.2 (CH2, NCH2), 50.3 (d, CH2, JC–P = 13.8 Hz,
NCH2P), 51.1 (d, CH2, JC–P = 15.4 Hz, NCH2P), 62.8 (CH2, allyl
trans-C), 62.9 (CH2, allyl trans-C), 69.2 (d, CH2, JC–P = 27.7 Hz,
allyl trans-P), 70.8 (CH2, NCH2N), 71.3 (d, CH2, JC–P = 26.2 Hz,
allyl trans-P), 111.4 (C5), 122.0 (CH, central allyl), 123.0 (CH,
central allyl), 127.2–136.2 (Ph), 142.3 (C, C4), 151.6 (C, CvO),
154.2 (C, CvO), 184.2 (d, C, JC–P = 19.0 Hz, carbene), 184.3 (d,
C, JC–P = 19.8 Hz, carbene).
31P{1H}-NMR (T = 298 K, D2O,
ppm) δ: −54.2, −53.1.
IR (KBr): νCO = 1708, 1668 cm
−1, νBF = 1062, 1084 cm
−1.
Anal. calcd for C24H33BF4N7O2PPd: C 42.66, H 4.92,
N 14.51. Found: C 42.52, H 4.99, N 14.32.
Synthesis of complex 6a
0.0173 g (0.047 mmol) of the dimer [Pd(μ-Cl)(η3-C3H5)]2 and
0.0124 g (0.094 mmol) of DIC (2,6-dimethylphenyl isocyanide)
were dissolved in ca. 20 mL of anhydrous CH3CN in a 50 mL
two necked flask under an inert atmosphere (Ar). The resulting
mixture was treated with 0.0344 g (0.043 mmol) of 3a/AgBF4
and stirred at RT for ca. 15 min.
The precipitated AgCl was removed by filtration on a
Millipore membrane filter.
Addition of diethyl ether to the concentrated solution
yielded the precipitation of complex 6a as a brownish solid,
which was filtered oﬀ on a Gooch and washed with n-pentane.
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0.0431 g of 6a was obtained (yield 88%).
1H-NMR (400 MHz, T = 298 K, CDCl3, ppm) δ: 2.41 (s, 6H,
2CH3
DIC), 3.20 (d, 1H, J = 13.3 Hz, anti allyl-H), 3.40 (s, 3H,
NCH3), 3.41 (d, 1H, J = 12.7 Hz, anti allyl-H), 3.88 (s, 3H,
NCH3), 4.05 (s, 3H, NCH3), 4.20 (s, 3H, NCH3), 4.47 (d, 1H, J =
6.4 Hz, syn allyl-H), 4.79 (d, 1H, J = 7.5 Hz, syn allyl-H), 5.72
(m, 1H, central allyl-H), 7.17–7.31 (m, 3H, PhDIC). 13C{1H}-NMR
(T = 298 K, CDCl3, ppm) δ: 18.7 (CH3, CH3
DIC), 28.6 (CH3,
NCH3), 32.0 (CH3, NCH3), 37.5 (CH3, NCH3), 39.3 (CH3, NCH3),
65.0 (CH2, allyl-C), 69.3 (CH2, allyl-C), 110.8 (C, C
5), 122.2
(central allyl), 128.4–135.6 (Ph), 141.4 (C, C4), 150.6 (C, CvO),
150.7 (C, CNDIC), 153.4 (C, CvO), 181.5 (C, carbene).
IR (KBr): νCN = 2175 cm
−1, νCO = 1706, 1665 cm
−1, νBF =
1056 cm−1.
Anal. calcd for C21H26BF4N5O2Pd: C 43.97, H 4.57, N 12.21.
Found: C 44.24, H 4.77, N 12.04.
Synthesis of complex 6b
Complex 6b was prepared in an analogous manner to that
described for 6a starting from 0.0180 g of [Pd(μ-Cl)(η3-allyl)]2,
0.0428 g of 3b/AgBF4 and 0.128 g of DIC.
0.0491 g (yield 85%) of 6b was obtained.
1H-NMR (400 MHz, T = 298 K, CDCl3, ppm) δ: 2.36 (s, 6H,
2CH3
DIC), 3.42 (s, 3H, NCH3), 3.48 (bd, 2H, 2anti allyl-H), 3.91
(s, 3H, NCH3), 4.24 (bd, 1H, syn allyl-H), 4.25 (s, 3H, NCH3),
4.67 (d, 1H, J = 7.5 Hz, syn allyl-H), 5.65 (s, 2H, NCH2), 5.73 (m,
1H, central allyl-H), 7.16–7.33 (m, 8H, Ph and PhDIC). 13C{1H}-
NMR (T = 298 K, CDCl3, ppm) δ: 18.8 (CH3, CH3
DIC), 28.7 (CH3,
NCH3), 32.1 (CH3, NCH3), 39.9 (CH3, NCH3), 53.0 (CH2, NCH2),
65.5 (CH2, allyl-C), 110.6 (C, C
5), 121.9 (CH, central allyl),
127.5–135.9 (Ph), 141.5 (C, C4), 150.5 (C, CvO), 150.7 (C,
CNDIC), 153.2 (C, CvO), 183.5 (C, carbene).
IR (KBr): νCN = 2175 cm
−1, νCO = 1709, 1670 cm
−1, νBF =
1057 cm−1.
Anal. calcd for C27H30BF4N5O2Pd: C 49.91, H 4.65, N 10.78.
Found: C 49.84, H 4.83, N 10.90.
Synthesis of complex 6d
Complex 6d was prepared in an analogous manner to that
described for 6a starting from 0.0184 g of [Pd(μ-Cl)(η3-allyl)]2,
0.0437 g of 3d/AgBF4 and 0.0131 g of DIC.
0.0543 g (yield 92%) of 6d was obtained.
1H-NMR (400 MHz, T = 298 K, CDCl3, ppm) δ: 2.41 (s, 6H,
2CH3
DIC), 3.19 (d, 1H, J = 13.5 Hz, anti allyl-H), 3.41 (d, 1H, J =
12.5 Hz, anti allyl-H), 3.86 (s, 3H, NCH3), 4.05 (s, 3H, NCH3),
4.19 (s, 3H, NCH3), 4.47 (d, 1H, J = 7.1 Hz, syn allyl-H), 4.78 (d,
1H, J = 7.5 Hz, syn allyl-H), 5.18 (s, 2H, NCH2), 5.72 (m, 1H,
central allyl-H), 7.17–7.49 (m, 8H, Ph and PhDIC). 13C{1H}-NMR
(T = 298 K, CDCl3, ppm) δ: 18.8 (CH3, CH3
DIC), 32.0 (CH3,
NCH3), 37.5 (CH3, NCH3), 39.3 (CH3, NCH3), 45.2 (CH2, NCH2),
64.9 (CH2, allyl-C), 110.9 (C, C
5), 122.2 (CH, central allyl),
127.8–136.3 (Ph), 141.5 (C, C4), 150.5 (C, CvO), 150.6 (C,
CNDIC), 153.2 (C, CvO), 181.8 (C, carbene).
IR (KBr): νCN = 2173 cm
−1, νCO = 1707, 1665 cm
−1, νBF =
1056 cm−1.
Anal. calcd for C27H30BF4N5O2Pd: C 49.91, H 4.65, N 10.78.
Found: C 50.04, H 4.51, N 10.95.
Synthesis of complex 8a
0.0156 g (0.086 mmol) of the dimer [Pd(μ-Cl)(η3-C3H5)]2 was
dissolved in ca. 20 mL of anhydrous CH3CN in a 50 mL two
necked flask under an inert atmosphere (Ar).
The resulting mixture was treated with 0.0690 g
(0.171 mmol) of 3a/AgBF4, 0.0142 g (0.086 mmol) of KI and
stirred at RT for ca. 15 min. The precipitated AgCl and AgI
were removed by filtration on a Millipore membrane filter.
Addition of diethyl ether to the concentrated solution yielded
the precipitation of complex 8a as a white solid, which was fil-
tered oﬀ on a Gooch and washed with n-pentane.
0.0446 g of 8a was obtained (yield 80%).
1H-NMR (400 MHz, T = 298 K, CD3CN, ppm) δ: 2.95 (d, 2H,
J = 13.3 Hz, anti allyl-H), 3.30 (s, 6H, NCH3), 3.73 (s, 6H,
NCH3), 3.93 (s, 6H, NCH3), 4.02 (s, 6H, NCH3), 4.12 (d, 2H, J =
7.4 Hz, syn allyl-H), 5.59 (m, 1H, central allyl-H). 13C{1H}-NMR
(T = 298 K, CD3CN, ppm) δ: 28.4 (CH3, NCH3), 32.0 (CH3,
NCH3), 37.7 (CH3, NCH3), 39.4 (CH3, NCH3), 61.6 (CH2, allyl-
C), 110.9 (C, C5), 121.0 (CH, central allyl), 141.9 (C, C4), 151.4
(C, CvO), 153.9 (C, CvO), 184.9 (C, carbene).
IR (KBr): νCO = 1706, 1668 cm
−1, νBF = 1053 cm
−1.
Anal. calcd for C21H29BF4N8O4Pd: C 38.76, H 4.49, N 17.22.
Found: C 38.50, H 4.82, N 17.35.
Synthesis of complex 8b
Complex 8b was prepared in an analogous manner to that
described for 8a starting from 0.0157 g of [Pd(μ-Cl)(η3-allyl)]2,
0.0822 g of 3b/AgBF4 and 0.0142 g of KI.
0.0599 g (yield 87%) of 8b was obtained.
1H-NMR (400 MHz, T = 298 K, CD3CN, ppm) δ: 2.79 (d, 2H,
J = 13.2 Hz, anti allyl-H), 3.23 (s, 6H, NCH3), 3.68 (s, 6H,
NCH3), 3.97 (s, 6H, NCH3), 3.97 (bd, 2H, syn allyl-H), 5.39–5.61
(m, 5H, NCH2 and central allyl-H), 6.94–7.24 (m, 10H, 2Ph).
13C{1H}-NMR (T = 298 K, CD3CN, ppm) δ: 28.3 (CH3, NCH3),
31.9 (CH3, NCH3), 39.6 (CH3, NCH3), 53.0 (CH2, NCH2), 65.9
(CH2, allyl-C), 110.4 (C, C
5), 121.2 (CH, central allyl),
125.7–137.2 (Ph), 142.0 (C, C4), 151.2 (C, CvO), 153.2 (C,
CvO), 185.3 (C, carbene).
IR (KBr): νCO = 1709, 1664 cm
−1, νBF = 1058 cm
−1.
Anal. calcd for C33H37BF4N8O4Pd: C 49.36, H 4.64, N 13.96.
Found: C 49.57, H 4.12, N 14.22.
Synthesis of complex 8c
Complex 8c was prepared in an analogous manner to that
described for 8a starting from 0.0157 g of [Pd(μ-Cl)(η3-allyl)]2,
0.0863 g of 3c/AgBF4 and 0.0142 g of KI.
0.0592 g (yield 81%) of 8c was obtained.
1H-NMR (400 MHz, T = 298 K, CD3CN, ppm) δ: 3.02 (s, 6H,
NCH3), 3.03 (d, 2H, J = 13.4 Hz, anti allyl-H), 3.53 (s, 6H,
NCH3), 4.20 (m, 8H, NCH3 and syn allyl-H), 5.44 (bs, 4H,
NCH2), 5.66 (m, 1H, central allyl-H), 7.16–7.48 (m, 10H, 2Ph).
13C{1H}-NMR (T = 298 K, CD3CN, ppm) δ: 28.4 (CH3, NCH3),
31.9 (CH3, NCH3), 39.8 (CH3, NCH3), 41.1 (CH2, NCH2), 65.9
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(CH2, allyl-C), 83.8 (CH2–C̲u), 84.7 (C, Ph–C̲u), 110.4 (C, C
5),
121.6 (CH, central allyl), 121.9–131.0 (Ph), 141.7 (C, C4), 150.5
(C, CvO), 153.4 (C, CvO), 185.5 (C, carbene).
IR (KBr): νCO = 1706, 1667 cm
−1, νBF = 1056 cm
−1.
Anal. calcd for C37H37BF4N8O4Pd: C 52.22, H 4.38, N 13.17.
Found: C 52.37, H 4.10, N 13.55.
Synthesis of complex 8d
Complex 8d was prepared in an analogous manner to that
described for 8a starting from 0.0154 g of [Pd(μ-Cl)(η3-allyl)]2,
0.0806 g of 3d/AgBF4 and 0.0139 g of KI.
0.0595 g (yield 88%) of 8d was obtained.
1H-NMR (400 MHz, T = 298 K, CD3CN, ppm) δ: 2.96 (d, 2H,
J = 13.3 Hz, anti allyl-H), 3.73 (s, 6H, NCH3), 3.93 (s, 6H,
NCH3), 4.02 (s, 6H, NCH3), 4.13 (d, 2H, J = 7.4 Hz, 2 syn
allyl-H), 5.13 (s, 4H, NCH2), 5.59 (m, 1H, central allyl-H),
7.28–7.39 (m, 10H, 2Ph).
13C{1H}-NMR (T = 298 K, CD3CN, ppm) δ: 31.5 (CH3, NCH3),
37.2 (CH3, NCH3), 38.8 (CH3, NCH3), 44.6 (CH2, NCH2), 61.1
(CH2, allyl-C), 110.4 (C, C
5), 120.4 (CH, central allyl),
127.4–137.3 (Ph), 141.5 (C, C4), 150.7 (C, CvO), 153.2
(C, CvO), 184.7 (C, carbene).
IR (KBr): νCO = 1708, 1667 cm
−1, νBF = 1058 cm
−1.
Anal. calcd for C33H37BF4N8O4Pd: C 49.36, H 4.64, N 13.96.
Found: C 49.61, H 4.17, N 14.05.
Growth inhibition assays
Cell growth inhibition assays were carried out using two
human ovarian cancer cell lines, A2780 and SKOV-3; A2780
cells are cisplatin-sensitive and SKOV-3 cells are cisplatin-
resistant. The cell lines were obtained from ATCC (Manassas,
VA) and maintained in RPMI 1640 supplemented with 10%
fetal bovine serum (FBS), penicillin (100 units per mL), strepto-
mycin (100 μg mL−1) and glutamine (2 mM) (complete
medium); the pH of the medium was 7.2 and the incubation
was performed at 37 °C under a 5% CO2 atmosphere. Adherent
cells were routinely used at 70% confluence and passaged
every 3 days by treatment with 0.05% trypsin-EDTA (Lonza).
Pure derivatives were added at serial dilutions and incu-
bated for 3 days. After this time, cells were washed with 1× PBS
and detached with trypsin. Cells were suspended in a physio-
logical solution and counted with a Z2 Coulter Counter
(Coulter Electronics, Hialeah, FL, USA). The cell number per
mL was determined as IC50 after 3 days of culture, when
untreated cells are in the log phase of cell growth.23,24 All stock
solutions were diluted in complete medium to give the final
concentrations. Cisplatin was employed as a control for the cis-
platin-sensitive A2780 and for the cisplatin-resistant SKOV3.
Untreated cells were placed in every plate as a negative control.
The cells were exposed to the compounds in 1000 μL total
volume for 72 hours.
Apoptosis assays
Annexin V and Dead Cell assays on A2780 and SKOV-3 cells,
untreated and treated for 72 h with increasing doses of palla-
dium complexes, were performed with the Muse cell analyzer
(Millipore, Billerica, MA, USA) method, according to the
instructions supplied by the manufacturer. This procedure uti-
lizes Annexin V to detect PS (PhosphatidylSerine) on the exter-
nal membrane of apoptotic cells. A dead cell marker is also
used as an indicator of cell membrane structural integrity.
Four populations of cells can be distinguished when using this
assay: live, early apoptotic, late apoptotic and dead cells. Cells
were washed with sterile 1× PBS, tripsinized, resuspended in
the original medium and diluted (1 : 2) with the one step
addition of the Muse Annexin V & Dead Cell reagent. After
20 min of incubation at room temperature, samples were ana-
lyzed using 0.01% Triton X as a positive control.25 Data from
the prepared samples were acquired and recorded utilizing the
Annexin V and Dead Cell Software Module (Millipore, Billerica,
MA, USA).
Crystal structure determination
The crystal data of 4a and 8d were collected at 100 K at the
XRD1 beamline of the Elettra Synchrotron, Trieste (Italy).26
The data sets were integrated and corrected for Lorentz and
polarization eﬀects using the XDS package.27 Data have been
scaled using the CCP4 Aimless code.28 Crystals of 8d showed
significant radiation damage upon exposure to X-rays; there-
fore data from three diﬀerent crystals were merged to obtain a
complete set of data. The structures were solved by direct
methods using the SHELXT program29 and refined using full-
matrix least-squares with all non-hydrogen atoms anisotropi-
cally and hydrogens included on calculated positions, riding
on their carrier atoms. Geometric restraints on bond lengths
and angles (DFIX, DANG) have been used in a 4a model for
disordered fragments (i.e. CH2Cl2 solvent molecule and BF4
−
ion). Thermal parameters restraints (SIMU, ISOR and isotropic
treatment of disordered allyl fragments) have been introduced
to successfully refine the structure of 8d, impaired by electron
density noise due to radiation damage eﬀects and non-mero-
hedral twinning (the structure was refined as a 2-component
twin, with domains related by twofold axis [1 0 0] and twin
fraction refined to 7%). All calculations were performed using
SHELXL-2017/1.30 The Coot program was used for structure
building.31 The crystal data are given in Table S1.† Pictures
were prepared using the Ortep332 software.
Crystallographic data have been deposited at the
Cambridge Crystallographic Data Centre and allocated the
deposition numbers CCDC 1825947 (for 4a) and 1825948
(for 8d).†
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